Navigation Links
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
Date:11/29/2007

ABBOTT PARK, Ill., Nov. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT)announced today that the Circulatory System Devices Advisory Panel to the U.S. Food and Drug Administration (FDA) recommended approval for the XIENCE(TM) V Everolimus Eluting Coronary Stent System. XIENCE V is a next-generation drug eluting stent intended for use in the treatment of coronary artery disease.

The FDA advisory committee voted to recommend the XIENCE V stent system for approval with conditions related to post-marketing study requirements and language related to dual antiplatelet therapy. The FDA is not required to, but usually follows the recommendations of its advisory committees.

"The clinical and angiographic benefits of the XIENCE V stent compared to the most widely used drug eluting stent available in the U.S. have been consistent and significant across the SPIRIT trials," said Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation, New York and principal investigator of the SPIRIT III clinical trial. "The robust body of safety and efficacy data support approval of XIENCE V as an important new technology that will enhance the lives of millions of patients with heart disease."

Abbott filed its Premarket Approval (PMA) submission for XIENCE V with the FDA on June 1, 2007. The PMA for XIENCE V is the first to include data demonstrating superiority of one drug eluting stent over another in the primary endpoint of in-segment late loss in a randomized controlled head-to-head trial with a market leading product.

"The outcome of today's advisory committee meeting is very encouraging," said John M. Capek, Ph.D., executive vice president, Medical Products, Abbott. "We look forward to bringing this important new treatment for coronary artery disease to physicians and patients in the U.S."

XIENCE V was launched in Europe and other international markets in 2006. XIENCE V is currently an investigational
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
3. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
4. Patient Safety Authority Board of Directors Names Infection Advisory Panel
5. Broker a Suite of Research & Advisory Services to Enhance Human Resources
6. Lynn Clark Callister, National Leader in Maternal-Child Health Nursing, Joins March of Dimes Advisory Council
7. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
8. Delta Dental Plans Association Forms National Scientific Advisory Committee
9. Alter+Care Creates the Advisory Board
10. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
11. Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 Standard advice ... test-drive and little else. However given industry’s less than ... to shoppers via the internet, Consumer Mattress Reports sets ... “ Choosing The Best Mattress .” , This article ... tips and suggestions that may not be readily apparent ...
(Date:5/21/2013)... Allen, TX (PRWEB) May 21, 2013 ... honored with the prestigious 2013 Top-Rated Award by GreatNonprofits ... , “We are excited to be named a Top-Rated 2013 ... happen without the dedication of our over 3000 Volunteers and ... is especially significant as it came from those that have ...
(Date:5/21/2013)... May 21, 2013 Parker Waichman LLP, a ... injured by defective medical devices, is offering remarks on the ... the Estate of Fred E. Taylor v. Intuitive Surgical, 09-2-03136-5, ... May 21, 2013, Bloomberg report noted that the ... a “car dealership” in how it deployed its strategy to ...
(Date:5/21/2013)... TX (PRWEB) May 21, 2013 ContinuCare ... the Texas Department of Aging and Disability Services. After ... and employee interviews, ContinuCare Home Health was found ... The review is part of the Department of Aging ... of aging and disability services, supports and opportunities ...
(Date:5/21/2013)... May 21, 2013 HealthSmart continues to ... national presence has required the hiring of new talent ... is pleased to announce that Dawn Powell has joined ... as the Director of Account Management in the Central ... in Irving, Texas. With extensive client management, employee benefits, ...
Breaking Medicine News(10 mins):Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2Health News:New Talent Joins the HealthSmart Account Management Team 2
... of the American College of Cardiology during,ceremonies at ... in Chicago, CHICAGO, April 1, 2008 ... Bluhm Cardiovascular Institute,of Northwestern Memorial Hospital, and Goldberg ... was recognized by the,American College of Cardiology (ACC) ...
... Leading consumer,employer and labor organizations today announced ... and health insurers on principles,to guide how ... the,information to consumers., The "Patient Charter ... announced today creates a national set of ...
... from people up to 75 had similar survival rates to ... News) -- People up to the age of 75 should ... National Eye Institute-funded study. , The researchers found that tissue ... success rate (86 percent) as corneas from donors aged 12 ...
... Your friend can eat whatever she wants and still fit into ... look at that chocolate cake. Before you sign up for Weight ... at some recent research from Tel Aviv University and save yourself ... to do with rigorous exercise and abstaining from sweets than it ...
... A new study has found that an x-ray dye ... prevent renal injury during percutaneous coronary intervention (PCI) in ... it made no difference in the need for dialysis ... the Contrast Media and Nephrotoxicity Following Coronary Revascularization by ...
... Speaker Denny Chipollini inspires others to hit the trails for ... Valley Forge Revolutionary 5-mile ... most people would,consider tragedies, 55-year-old Skippack, Pa., resident Denny Chipollini,considers ... loss of his leg in a near-fatal car accident and ...
Cached Medicine News:Health News:Robert Bonow, MD Honored for Outstanding Service by the American College of Cardiology 2Health News:Robert Bonow, MD Honored for Outstanding Service by the American College of Cardiology 3Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 2Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 3Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 4Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 5Health News:Study Finds Older Corneas Suitable for Transplantation 2Health News:The lean gene 2Health News:Iso-osmolar X-ray dye falters in PCI study 2Health News:Iso-osmolar X-ray dye falters in PCI study 3Health News:For Inspiring Amputee It's No Excuses, No Limits 2
(Date:5/21/2013)... 21, 2013  BioRestorative Therapies, Inc. ("BRT" or the ... on developing stem cell based therapies for various personal ... its President and CEO, will be presenting at the ... be held on Thursday, May 30, 2013 at the ... in New York City.  Mr. Weinreb,s presentation will take ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... MONROVIA, Calif. , May 21, 2013 ... leading developer, manufacturer and marketer of minimally invasive ophthalmic ... upcoming investor conferences to review the Company,s recent financial ... STAAR Surgical will present at the 38 ... Boston at the Westin Waterfront ...
Breaking Medicine Technology:BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5STAAR Surgical To Present At Upcoming Investor Conferences 2
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
Cannulated Interference Screws...
... Cannulated Interference Screws. ... strength and graft selection ... easily without deformation, and ... full threaded atraumatic tissue ...
... Mini-TrueView Arthroscopes,Based on the TrueView II design, ... optic telescopes for small joint arthroscopy is ... autoclavable and very durable thanks to Olympus ... new telescope class means bright images, brilliant ...
... The SOVEREIGN System offers new WHITESTAR Technology, ... phaco. WHITESTAR Technology dramatically reduces the amount ... while still providing full ultrasound cutting efficiency. ... fragments are drawn safely and efficiently to ...
Medicine Products: